Advances in ophthalmic preparation: the role of drug nanocrystals and lipid-based nanosystems

References

• Grand View Research [Internet]. San Francisco (US-CA): Grand View Research; [cited 2019 Apr]. Available from: https://www.grandviewresearch.com/industry-analysis/ophthalmic-therapeutics-drug-market.
   Google Scholar
• Transparency Market Research [Internet]. Albany (NY): Transparency Market Research; [cited 2017 Jul]. Available from: https://www.transparencymarketresearch.com/ophthalmic-drugs-market.html.
   Google Scholar
• Allied Market Research [Internet]. Portland (OR): Allied Market Research; [cited 2017 Nov]. Available from: https://www.alliedmarketresearch.com/ophthalmic-drugs-market.
   Google Scholar
• Zion Market Research [Internet]. New York (NY): GlobeNewswire; [cited 2018 Sep 21]. Available from: https://globenewswire.com/news-release/2018/09/21/1574283/0/en/Global-Ophthalmic-Drugs-Market-Expected-to-Reach-USD-34-52-Billion-By-2024-Zion-Market-Research.html.
   Google Scholar
• World Health Organization [Internet]. Geneva: World Health Organization; [cited 2019] Available from: http://www.who.int/blindness/causes/priority/en/.
   Google Scholar
• de Souza A, Marins DSS, Mathias SL, et al. Promising nanotherapy in treating leishmaniasis. Int J Pharm. 2018;547(1–2):421–431.
   PubMedGoogle Scholar
• Sánchez-López E, Espina M, Doktorovova S, et al. Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye – Part I – Barriers and determining factors in ocular delivery. Eur J Pharm Biopharm. 2017;110:70–75.
   PubMed Web of Science ®Google Scholar
• Rodríguez Villanueva J, Rodríguez Villanueva L. Turning the screw even further to increase microparticle retention and ocular bioavailability of associated drugs: the bioadhesion goal. Int J Pharm. 2017;531(1):167–178.
   PubMedGoogle Scholar
• Sharma OP, Patel V, Mehta T. Nanocrystal for ocular drug delivery: hope or hype. Drug Deliv Transl Res. 2016;6(4):399–413.
   PubMed Web of Science ®Google Scholar
• Lam SM, Tong L, Duan X, et al. Extensive characterization of human tear fluid collected using different techniques unravels the presence of novel lipid amphiphiles. J Lipid Res. 2014;55(2):289–298.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhao SZ, Koh SK, et al. In-depth analysis of the human tear proteome. J Proteomics. 2012;75(13):3877–3885.
   PubMed Web of Science ®Google Scholar
• Cwiklik L. Tear film lipid layer: a molecular level view. Biochim Biophys Acta - Biomembr. 2016;1858(10):2421–2430.
   Web of Science ®Google Scholar
• Achouri D, Alhanout K, Piccerelle P, et al. Recent advances in ocular drug delivery. Drug Dev Ind Pharm. 2013;39(11):1599–1617.
   PubMed Web of Science ®Google Scholar
• Ammar HO, Salama HA, Ghorab M, et al. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10(3):808–819.
   PubMed Web of Science ®Google Scholar
• Gao L, Liu G, Ma J, et al. Drug nanocrystals: in vivo performances. J Control Rel. 2012;160(3):418–430.
   PubMed Web of Science ®Google Scholar
• Romero GB, Keck CM, Müller RH, et al. Development of cationic nanocrystals for ocular delivery. Eur J Pharm Biopharm. 2016;107:215–222.
   PubMed Web of Science ®Google Scholar
• Janagam DR, Wu L, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev. 2017;122:31–64.
   PubMed Web of Science ®Google Scholar
• Madni A, Rahem MA, Tahir N, et al. Non-invasive strategies for targeting the posterior segment of eye. Int J Pharm. 2017;530(1–2):326–345.
   PubMedGoogle Scholar
• Weng Y, Liu J, Jin S, et al. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B. 2017;7(3):281–291.
   PubMed Web of Science ®Google Scholar
• Holland E, Mannis M, Lee WB. Ocular surface disease: cornea, conjunctiva and tear film. London: Elsevier Health Sciences; 2013.
   Google Scholar
• Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug delivery. AAPS J. 2010;12(3):348–360.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Schmitt M, Bourges JL, et al. Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14–28.
   PubMed Web of Science ®Google Scholar
• Philips B, Bague S, Rabinovich-Guilatt, Lamber G, et al. inventors; NOVAGALI PHARMA SA, assignee. Ophthalmic Emulsions containing an immunosuppressive agent. World Intellectual Property Organization patent WO2006050837. 2006.
   Google Scholar
• Chen ML, John M, Lee SL, et al. Development considerations for nanocrystal drug products. AAPS J. 2017;19(3):642–651.
   PubMed Web of Science ®Google Scholar
• Modi SS, Lehmann RP, Walters TR, et al. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study. J Cataract Refract Surg. 2014;40(2):203–211.
   PubMed Web of Science ®Google Scholar
• Castillo JE, Asgharian B, Chowhan MA, inventors; Alcon Research Ltd., assignee Stabilized Pharmaceutical sub-micron suspensions and methods of forming same. United States patent US 20100076045. 2010.
   Google Scholar
• Ousler G, Devries DK, Karpecki PM, et al. An evaluation of retaineTM ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye. Clin Ophthalmol. 2015;9:235–243.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. J Drug Deliv. 2012;2012:1–16.
   Google Scholar
• European Medicines Agency [Internet]. Evry Cedex: SANTEN. Available from: https://ec.europa.eu/health/documents/community-register/2015/20150319131066/anx_131066_en.pdf.
   Google Scholar
• Santen [Internet]. Osaka: Santen Pharmaceutical Co; [cited2016]. Available from: http://www.santen.com/en/news/20160512.pdf.
   Google Scholar
• Santen [Internet]. Osaka: Santen Pharmaceutical Co; [cited 2019 Aug 1] Available from: https://www.santen.com/en/rd/pdf/pipeline.pdf
   Google Scholar
• Tuomela A, Liu P, Puranen J, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014;467(1–2):34–41.
   PubMed Web of Science ®Google Scholar
• Müller RH, Ma K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.
   PubMed Web of Science ®Google Scholar
• Malamatari M, Taylor KMG, Malamataris S, et al. Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today. 2018;23(3):534–547.
   PubMed Web of Science ®Google Scholar
• Ali HSM, York P, Ali AMA, et al. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Rel. 2011;149(2):175–181.
   PubMed Web of Science ®Google Scholar
• Kassem MA, Abdel Rahman AA, Ghorab MM, et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340(1–2):126–133.
   PubMedGoogle Scholar
• Baba K, Nishida K. Steroid nanocrystals prepared using the nano spray dryer B-90. Pharmaceutics. 2013;5(4):107–114.
   PubMedGoogle Scholar
• Nagai N, Ono H, Hashino M, et al. Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles. J Oleo Sci. 2014;63(2):177–186.
   PubMed Web of Science ®Google Scholar
• Nagai N, Ito Y, Okamoto N, et al. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology. 2014;319:53–62.
   PubMed Web of Science ®Google Scholar
• Deguchi S, Otake H, Nakazawa Y, et al. Ophthalmic formulation containing nilvadipine nanoparticles prevents retinal dysfunction in rats injected with streptozotocin. Int J Mol Sci. 2017;18:pii: E2720.
   Web of Science ®Google Scholar
• Gupta S, Samanta MK, Raichur AM. Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy. AAPS PharmSciTech. 2010;11(1):322–335.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]. London: Committee for Human Medicinal Products (CHMP); [cited 2014. Nov 20]. Available from: https://www.ema.europa.eu/documents/report/background-review-cyclodextrins-used-excipients-context-revision-guideline-excipients-label-package_en.pdf.
   Google Scholar
• Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–2387.
   PubMed Web of Science ®Google Scholar
• Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-A review. J Control Rel. 2008;128(3):185–199.
   PubMed Web of Science ®Google Scholar
• Sonneville-Aubrun O, Yukuyama MN, Pizzino A. Chapter 14 – application of nanoemulsions in cosmetics. Nanoemulsions. 2018:435–475.
   Google Scholar
• Solans C, Solé I. Nano-emulsions: formation by low-energy methods. Curr Opin Colloid Interface Sci. 2012;17(5):246–254.
   Web of Science ®Google Scholar
• Dario MF, Santos M, Viana AS, et al. A high loaded cationic nanoemulsion for quercetin delivery obtained by sub-PIT method. Colloids Surfaces A Physicochem Eng Asp. 2016;489:256–264.
   Web of Science ®Google Scholar
• Sagitani M, Nabeta H, Nagai K. A New preparing method for fine O/W emulsions by D phase emulsification and their application to cosmetic industry. J Jpn Oil Chem Soc. 1991;40(11):988–994.
   Google Scholar
• Yukuyama MN, Oseliero PLF, Kato ETM, et al. High internal vegetable oil nanoemulsion: D-phase emulsification as a unique low energy process. Colloids Surf A Physicochem Eng Asp. 2018;554:296–305.
   Web of Science ®Google Scholar
• Solans C, Izquierdo PJ, Nolla J, et al. Nano-emulsions. Curr Opin Coll Interf Sci. 2005;10:102–110.
   Web of Science ®Google Scholar
• Ganta S, Talekar M, Singh A, et al. Nanoemulsions in translational research - Opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech. 2014;15(3):694–708.
   PubMed Web of Science ®Google Scholar
• Akhter S, Anwar M, Siddiqui MA, et al. Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: formulation development, in-vitro and in-vivo studies. Colloid Surf B Biointerf. 2016;148:19–29.
   PubMed Web of Science ®Google Scholar
• Kalam MA, Sultana Y, Ali A, et al. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin. J Biomed Mater Res. 2013;101 A:1813–1827.
   Web of Science ®Google Scholar
• Abul Kalam M, Sultana Y, Ali A, et al. Part II: enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops. J Biomed Mater Res. 2013;101 A:1828–1836.
   Web of Science ®Google Scholar
• Başaran E, Demirel M, Sirmagül B, et al. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul. 2010;27(1):37–47.
   PubMed Web of Science ®Google Scholar
• Gökçe EH, Sandri G, Eğrilmez S, et al. Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res. 2009;34(11):996–1003.
   PubMed Web of Science ®Google Scholar
• Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008;364(1):76–86.
   PubMedGoogle Scholar
• Liu Z, Zhang X, Wu H, et al. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm. 2011;37(4):475–481.
   PubMed Web of Science ®Google Scholar
• Li N, Han Z, Li L, et al. The anti-cataract molecular mechanism study in selenium cataract rats for baicalin ophthalmic nanoparticles. DDDT. 2018;12:1399–1411.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Sahoo PK, Majumdar DK, et al. Fabrication and evaluation of lipid nanoparticulates for ocular delivery of a COX-2 inhibitor. Drug Deliv. 2016;23(9):3364–3373.
   PubMed Web of Science ®Google Scholar
• Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm. 2016;109:224–235.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao F, Liu R, et al. Novel cationic lipid nanoparticles as an ophthalmic delivery system for multicomponent drugs: development, characterization, in vitro permeation, in vivo pharmacokinetic, and molecular dynamics studies. Int J Nanomed. 2017;12:8115–8127.
   PubMed Web of Science ®Google Scholar
• Li R, Jiang S, Liu D, et al. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J Microencapsul. 2011;28(2):134–141.
   PubMed Web of Science ®Google Scholar
• Youshia J, Kamel AO, Shamy A, et al. Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Int J Nanomed. 2012;7:2483–2496.
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang M, Zhang D, et al. Preparation, optimization, and characterization of chitosan-coated solid lipid nanoparticles for ocular drug delivery. J Biomed Res. 2018;32(5):411–423.
   PubMedGoogle Scholar
• Leonardi A, Bucolo C, Drago F, et al. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. Int J Pharm. 2015;478(1):180–186.
   PubMed Web of Science ®Google Scholar
• Shen J, Sun M, Ping Q, et al. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology. 2010;21(2):025101.
   PubMed Web of Science ®Google Scholar
• Shen J, Deng Y, Jin X, et al. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm. 2010;402(1–2):248–253.
   PubMedGoogle Scholar
• Gonzalez-Mira E, Egea MA, Garcia ML, et al. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Coll Surf B Biointerf. 2010;81(2):412–421.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Mira E, Egea MA, Souto EB, et al. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology. 2011;22(4):045101.
   PubMed Web of Science ®Google Scholar
• Araújo J, Gonzalez-Mira E, Egea MA, et al. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm. 2010;393(1–2):168–176.
   Google Scholar
• Li J, Liu D, Tan G, et al. A comparative study on the efficiency of chitosan-N-acetylcysteine, chitosan oligosaccharides or carboxymethyl chitosan surface modified nanostructured lipid carrier for ophthalmic delivery of curcumin. Carbohydr Polym. 2016;146:435–444.
   PubMed Web of Science ®Google Scholar
• Üstündaǧ-Okur N, Gökçe EH, Bozbiyik DI, et al. Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis. Eur J Pharm Sci. 2014;63:204–215.
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhao J, Zhang X, et al. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011;403(1–2):185–191.
   PubMed Web of Science ®Google Scholar
• Zhang W, Li X, Ye T, et al. Nanostructured lipid carrier surface modified with Eudragit RS 100 and its potential ophthalmic functions. Int J Nanomed. 2014;9:4305–4315.
   PubMed Web of Science ®Google Scholar
• Liu R, Liu Z, Zhang C, et al. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. J Pharm Sci. 2012;101(10):3833–3844.
   PubMed Web of Science ®Google Scholar
• Puglia C, Blasi P, Ostacolo C, et al. Innovative nanoparticles enhance N-palmitoylethanolamide intraocular delivery. Front Pharmacol. 2018;9:1–7.
   PubMed Web of Science ®Google Scholar
• Gasco MR, inventor. Method for producing solid lipid microspheres having a narrow size distribution. United States patent US 5,250,236. 1993 Oct 05.
   Google Scholar
• Müller RH, Maaßen S, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int J Pharm. 1996;138(1):85–94.
   Web of Science ®Google Scholar
• Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie. 2006;61:375–386.
   PubMed Web of Science ®Google Scholar
• Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm. 2008;34(12):1394–1405.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing S. A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(1):S131–S55.
   PubMed Web of Science ®Google Scholar
• Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm. 2013;39(4):508–519.
   PubMed Web of Science ®Google Scholar
• Radtke M, Souto EB, Müller RH. Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. Pharm Technol Eur. 2005;17:1–4.
   Google Scholar
• Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1–2):170–184.
   PubMed Web of Science ®Google Scholar
• Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–580.
   PubMed Web of Science ®Google Scholar